TFX

In April 2026, Teleflex announced a significant strategic pivot, including a $2.03 billion divestiture of three legacy business units (urology and acute care segments) and a concurrent $1 billion accelerated share buyback program, aimed at focusing on a leaner, higher-margin core business. The stock was trading in the $115-$120 range at the beginning of 2026, and Raymond James upgraded TFX to "Outperform" in April 2026. In June 2026, Jason Weidman was appointed President and CEO. The company also completed a $500 million senior notes offering and repurchased $250 million of common stock as part of its share buyback program. In July 2026, the FDA approved EZPLAZ Freeze Dried Plasma, expanding Teleflex's emergency medicine offerings, and the company published its 2025 Global Impact Report. Teleflex reported its Q2 CY2026 financial results in August 2026, exceeding market expectations with revenue from continuing operations of $570.3 million (up 28.9% year-on-year) and adjusted diluted EPS of $1.76. The Vascular and Surgical segments showed strong growth, while the Interventional segment saw a slight decline. The company completed the sale of its OEM business and used proceeds to reduce debt, improving its pro forma net leverage to approximately 1.9X. In September 2026, BofA upgraded Teleflex to "Buy" from "Neutral" and adjusted its price target to $158 from $145. A peer-reviewed study also demonstrated a significant reduction in CLABSI risk with Teleflex's Arrowg+ard™ Technology. As of October 2026, the stock is trading around $125.01, with analysts holding a "Moderate Buy" consensus rating and an average price target of $155.20.